Core Viewpoint - Tibet Pharmaceutical (600211) is advancing its research and development efforts, particularly focusing on innovative treatments for specific medical conditions, including ATTR and familial hypercholesterolemia [1] Group 1: Product Development - The main product under development by Ruizheng Gene is ART001, targeting transthyretin amyloidosis (ATTR), which received IND approval in both China and the United States last year and is currently undergoing Phase I/IIa clinical trials in China [1] - Another product, ART002, is aimed at PCSK9 and is currently in an investigator-initiated trial (IIT) for familial hypercholesterolemia, although it has not yet obtained clinical approval [1] Group 2: Research and Development Investment - The company plans to adjust its future R&D expenditure based on the progress of its ongoing research projects [1]

Core Viewpoint - The company emphasizes the importance of capital operations and mergers and acquisitions (M&A) as part of its strategic goals, supported by strong cash flow and performance metrics for management [1] Group 1: Capital Operations - The company has sufficient cash flow that provides direct and flexible funding for ongoing M&A investments [1] - Capital operations and M&A outcomes are included in the key performance indicators for the management team [1] Group 2: Growth Strategy - The company adopts a strategy of "internal growth + external growth" to stabilize its core business while exploring new opportunities [1] - The core product, Xinhuasuan, will continue to generate stable cash flow and profit contributions in the untapped heart failure market [1] - Accelerated growth of other proprietary products will further solidify a diversified revenue base, enhancing overall risk resistance [1] Group 3: Innovation and Product Pipeline - The company is actively pursuing external M&A and innovative project layouts to build a product pipeline that combines short-term, medium-term, and long-term offerings [1] - This approach aims to reduce reliance on a single product and inject continuous growth momentum into the company [1]

Core Viewpoint - Xizang Pharmaceutical (600211) has developed Zolertinib, the world's first drug specifically targeting advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases, achieving significant results in clinical trials [1] Group 1 - Zolertinib is the only EGFR tyrosine kinase inhibitor (EGFR-TKI) designed with a substrate for non-blood-brain barrier efflux proteins, demonstrating 100% ability to penetrate the blood-brain barrier [1] - The drug received approval for market launch in November 2024 and was successfully included in the national medical insurance catalog in December 2025, which opens up sales channels for the future [1] - However, due to the time required for market introduction and hospital access for new drugs, it is expected that the revenue from this product will not significantly impact the company in 2026 [1]

Core Viewpoint - Xizang Pharmaceutical's new drug, Xinhuasu, is positioned favorably in the domestic heart failure treatment market, facing limited competition as most rivals are still in clinical stages [2] Group 1: Market Position and Competition - Xinhuasu is currently the only approved biological drug for heart failure treatment in China, with Suzhou Landin's related products being the only competition that has been approved for market [2] - The company aims to consolidate and expand its market advantage through a three-pronged strategy: channel deepening, academic enhancement, and diversified product pipeline [2] Group 2: Strategic Initiatives - Channel Deepening and Terminal Coverage: Xinhuasu has entered nearly 7,000 hospital terminals, ensuring a broad coverage and stable foundation. The company plans to collaborate with commercial partners to integrate channel resources and expand into secondary hospitals and grassroots medical markets, thereby increasing terminal penetration [2] - Strengthening Evidence-Based Medical Support: The company has initiated exploratory research on evidence-based medicine for Xinhuasu, aiming to bolster the product's academic standing with robust clinical data and promote its application in more clinical scenarios [2] - Building a Diversified Product Pipeline: To reduce reliance on a single product, the company is actively pursuing strategic transformation by accelerating the market layout of its proprietary traditional Chinese medicine products and seeking new growth points through external collaborations and investments [2] Group 3: Market Potential - According to the 2023 Journal of Clinical Cardiovascular Diseases, there are approximately 12.1 million heart failure patients over the age of 25 in China, with about 3 million new cases each year. The current penetration rate of Xinhuasu remains low, indicating significant market potential amid an aging population and ongoing clinical demand [2]

Group 1 - The company plans to provide a guarantee of up to RMB 120 million for its subsidiary Accuredit Therapeutics Limited to support the operational and R&D funding needs of its wholly-owned subsidiary, Ruizheng Suzhou [1][2] - The guarantee is deemed necessary and reasonable as it enhances the flexibility of fund utilization and supports the stable operation and long-term development of the subsidiaries [2][3] - The board of directors approved the guarantee proposal with unanimous support, indicating confidence in the operational and financial stability of the subsidiaries [2][3] Group 2 - As of the announcement date, the total amount of external guarantees provided by the company and its subsidiaries is RMB 800 million, which accounts for 20.24% of the company's latest audited net assets [4] - The actual balance of external guarantees is RMB 780 million and USD 1.57 million, representing 20.01% of the company's latest audited net assets [4] - The company has not provided guarantees to its controlling shareholders or related parties, and there are no overdue guarantees [4] Group 3 - The company will hold its first extraordinary shareholders' meeting of 2026 on February 25, 2026, with both on-site and online voting options available [5][6] - The meeting will take place at the company's office in Chengdu, Sichuan Province, starting at 14:30 [6] - Shareholders can register for the meeting from February 12, 2026, and are encouraged to participate through the Shanghai Stock Exchange's online voting system [12][15]

Group 1 - The company Tibet Pharmaceutical announced that as of the date of the announcement, the total amount of external guarantees provided by the company and its subsidiaries is 800 million RMB, all of which are guarantees for its subsidiaries, accounting for 20.24% of the company's most recent audited net assets [1] - The actual balance of external guarantees that have occurred is 780 million RMB and 157 million USD, which accounts for 20.01% of the company's most recent audited net assets [1] - The company has not provided guarantees for its controlling shareholders, actual controllers, or their related parties, and there have been no overdue guarantees [1]

证券代码：600211 证券简称：西藏药业 公告编号：2026-005 西藏诺迪康药业股份有限公司 关于控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供 的担保余额 | 是否在前 | 本次担保 | | --- | --- | --- | --- | --- | | | | （不含本次担 | 期预计额 | 是否有反 | | | | 保金额） | 度内 | 担保 | | 锐正基因（苏州）有限公司 | | | | | | （以下简称"锐正苏州"） | | | | | | 及锐正基因科技（上海）有 | 12,000 万元人民币 | 157 万美元 | 否 | 是 | | 限公司（"锐正上海"）， | | | | | | 本次担保不存在关联担保。 | | | | | 注：上述"实际为其提供的担保余额"为本公司控股子公司 Accuredit Therapeutics Limited 下 属全资子公司 Accuredit The ...

证券代码：600211 证券简称：西藏药业 公告编号：2026-006 西藏诺迪康药业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 召开的日期时间：2026 年 2 月 25 日 14 点 30 分 召开地点：四川省成都市锦江区三色路 427 号公司办公楼会议室 至2026 年 2 月 25 日 股东会召开日期：2026年2月25日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方式 (四) 现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会召开 当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投 票时间为股东会召开当日的 9:15-15:00。 ...

Group 1 - The company, Tibet Pharmaceutical, announced that as of January 31, 2026, it has repurchased a total of 4,000,058 shares through the Shanghai Stock Exchange, accounting for 1.24% of its total share capital [2] - The highest purchase price for the repurchased shares was 45.98 yuan per share, while the lowest was 42.66 yuan per share [2] - The total amount paid for the repurchased shares was 177,595,651.46 yuan, excluding transaction fees such as stamp duty and commissions [2]

证券代码：600211 证券简称：西藏药业 公告编号：2026-004 西藏诺迪康药业股份有限公司 关于回购股份的进展公告 截至 2026 年 1 月月底，公司通过上海证券交易所交易系统以集中竞价交易方式已累计 回购公司股份 4,000,058 股，占公司总股本的比例为 1.24%，购买的最高价为 45.98 元/股， 最低价为 42.66 元/股，已支付的总金额为人民币 177,595,651.46 元（不含印花税、交易 佣金等交易费用）。 上述回购股份符合相关法律法规的规定及公司回购方案的要求。 一、回购股份的基本情况 2025 年 12 月 18 日，公司召开第八届董事会第四次临时会议，审议通过了《关于以集 中竞价交易方式回购股份的议案》，同意公司使用自有资金通过上海证券交易所股票交易系 统以集中竞价交易方式回购公司发行的人民币普通股 A 股股票，回购资金不低于人民币 17,000 万元（含），不高于人民币 20,000 万元（含），本次回购的股份将用于实施股权激 励或员工持股计划，回购价格不超过人民币 55 元/股（含）；回购股份的实施期限为自公司 董事会审议通过本次回购股份方案之日起不超过 12 个 ...